Immune Checkpoint Inhibitors Improve Outcomes in Mismatch Repair Deficient CRC, but Can Induce irAEs
Treatment of colorectal cancer (CRC)—the third leading cause of cancer-related death in the United States—remains challenging even today. But according to leading oncologists in the field, ...
Lynch syndrome (LS)–associated colorectal cancer (CRC) is characterized by mismatch repair-deficiency (MMR-D) and/or microsatellite instability (MSI). However, with increasing utilization of germline ...
Research from The University of Texas MD Anderson Cancer Center has tried to fill the knowledge gaps that exist in the treatment of colorectal cancers that harbor mutations in genes involved in DNA ...
The discovery of immune checkpoints and their role in regulating host immune response to cancer has provided therapeutic targets for clinicians. Although there are now many recognized immune ...
Patients with resectable mismatch repair-proficient and -deficient colorectal cancer had robust responses to neoadjuvant botensilimab/balstilimab. Patients with ...
Testing for mismatch repair (MMR) and microsatellite instability (MSI) among patients with colorectal cancer (CRC) increased from 22.7% in 2012 to 71.5% in 2021, but variations in access remain, with ...
Colorectal cancers (CRCs) with deficiency in the mismatch repair (MMR) genes, such as MLH1, MSH2 or MSH6, are classified as Lynch syndrome, and patients with such cancer are at higher risk for other ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results